Videos

As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Karl Csaky, MD and Fredrick Ferris III, MD, identified in 2007—Dr. Csaky reinforces on the importance of preserving the central retinal tissue.

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.

At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.

The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.

The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.

Catching up after ASCRS 2022, Ora's Caitlin Black, senior director and therapeutic area head of medical devices, talks about the next generation of ophthalmic device therapies and diagnostics, clinical trial updates and new innovations that are most exciting for presbyopia treatment.

Penny Asbell, MD, FACS, MBA, discusses “Antibiotic Resistance among Ocular Staphylococcal Pathogens: Longitudinal Trends in the ARMOR Study."

Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.

Diana Do, MD, professor of ophthalmology at Stanford's Byers Eye Institute, presents research on a newly developed, novel patient-reported outcome instrument (PRO) for patients who have proliferative diabetic retinopathy and who are undergoing treatment with either intravitreal anti-VEGF therapy, or panretinal photocoagulation.

There is a shortage of neuro-opthalmologists in the US, and Andy Lee, MD, and Elizabeth Fortin, MD, look at recent survey results diving into this topic.

A second FDA indication for the treatment of allergic conjunctivitis proves promising for patient relief.

Two year data shows a promising future for the OCD guided, noninvasive technology for glaucoma treatment.

Alex Dastgheib, MD, ABO, discusses the findings of the paper, "325 Cases of Phacoemulsification in Blind Cataracts," presented at the 2022 ASCRS conference in Washington, DC. The paper won the Challenging Cases session during the meeting.

Newer generation formulas generally outperformed older generation formulas, with SRK/T performing the best of older formulas, especially when using TK values.

Jennifer I. Lim, MD, FARVO, FASRS, reviews the 2-year results of the YOSEMITE and RHINE trials, outlining the efficacy, durability, and safety of faricimab in diabetic macular edema.

Older generation non-LVC formulas show marked improvement upon using TK values vs K, while multivariable non-LVC formulas did not consistently improve.

Jonathan Solomon, MD, shares his personal experience using the Beyeonics One exoscope, highlighting what makes this tool stand out.

Results concluded that K did better than TK in a variety of situations.

Edward Hu, MD, PhD, looked at 812 toric IOLs utilized of various platforms, concluding a low total toric rotation rate at 2.1%.

The study assesses and compares the accuracy of IOL formulas using keratometry (K) and total keratometry (TK) values obtained by a swept-source OCT biometer (IOL Master 700) in eyes with previous PKP prior to cataract surgery.

There is considerable variability in variables when measuring the eyes with both biometers, which may affect formula performance and postoperative refractive predictions when using formulas that utilize values like interior chamber depth and lens thickness.

Allie Holmes, head of US marketing for Johnson & Johnson Surgical Vision, shares an update on what visioning the company is doing with their new and elevated technologies.

Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.

Joseph Panarelli, MD, and Arsham Sheybani, MD, discuss the Primary Trabeculectomy for Advanced Glaucoma: Pragmatic Multicentre Randomized Controlled Trial, or TAGS trial, and how this can apply to real world situation. This multicenter randomized controlled trial evaluated whether primary trabeculectomy or primary medical treatment leads to improved outcomes in terms of quality of life, clinical effectiveness, and safety.

At ARVO 2022, Jason S. Slakter, MD, presents data on the efficacy and safety of OPT-302 when combined with ranibizumab for polypoidal choroidal vasculopathy.

Riad Sherif, MD, CEO of Oculis, gives a company update on clinical trials for products in DME, ocular surgery, and more; plus, growing products in glaucoma treatments, team and financing updates.

Kevin Waltz, a consultant for ViaLase, discusses the company's technology: an image-guided femtosecond laser surgical system for the treatment of glaucoma.